A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Trial Profile

A Phase 1b, Open Label Study of Dalantercept Plus Sorafenib in Patients With Advanced Hepatocellular Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 19 Jul 2017

At a glance

  • Drugs Dalantercept (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Adverse reactions
  • Acronyms The DASH Study
  • Sponsors Acceleron Pharma
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 22 Nov 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2017.
    • 22 Nov 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top